Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT

Mansour Mustafa¹, Dhruv Patel¹, Lily Shen¹, Anita Shetty², and Robert Mansberg¹,³

¹Nuclear Medicine and PET Department Nepean Hospital, Penrith, New South Wales, Australia; ²Department Haematology, Nepean Hospital, Penrith, New South Wales, Australia; and ³Sydney Medical School Nepean, University of Sydney, New South Wales, Australia

Corresponding Author:
Robert Mansberg, MD
Nuclear Medicine Nepean Hospital, Penrith,
New South Wales, Australia 2571;
E-mail: mansberg@usyd.edu.au

Key Words: hodgkin disease, granulomatous lymphangitis, PET/CT, relapse
Abbreviations: Fludeoxyglucose (¹⁸F) positron emission tomography/computed tomography (FDG PET/CT), computed tomography (CT), maximum intensity projection (MIP)

ABSTRACT

A 38-year-old woman with Hodgkin lymphoma was referred for staging fludeoxyglucose (¹⁸F) positron emission tomography/computed tomography (FDG PET/CT) that showed widespread intensely FDG-avid disease in multiple nodal stations above the diaphragm and spleen and extranodal involvement in the lungs and vertebral bodies. She underwent chemotherapy and radiotherapy. Progress FDG PET/CT 5 months later showed significant metabolic and anatomic response. Repeat FDG PET/CT 1 month later was highly suspicious of recurrent disseminated FDG-avid lymphoma in multiple nodal stations above and below the diaphragm, spleen, multiple bones, and lungs. Subsequent bone marrow biopsy showed sarcoid-like granulomatous inflammation with no evidence of lymphoma. The patient was clinically well and no active treatment was instituted. Subsequent FDG PET/CT 2 months later showed complete resolution of metabolic activity.

INTRODUCTION

Fludeoxyglucose (¹⁸F) (FDG) uptake in positron emission tomography/computed tomography (FDG PET/CT) is based on identifying increased glycolytic activity in malignant cells. Lymphoma is a malignancy that originates in the lymphocytes. FDG-PET/CT has high sensitivity in detecting nodal disease and extranodal in lymphoma (Hodgkin and non-Hodgkin) and is currently the preferred method of staging, assessment of treatment response, restaging, and surveillance. FDG PET/CT has supplanted conventional imaging techniques such as gallium scintigraphy, computed tomography (CT) or magnetic resonance imaging (1).

Nonmalignant processes such as infection, inflammation, and granulomatous disease (such as sarcoidosis or sarcoid-like reaction) can also show high FDG uptake and can mimic a malignant process on FDG PET/CT. Nonmalignant conditions causing FDG uptake in lymph nodes (enlarged or nonenlarged) such as infection and granulomatous disease are not infrequent; however, the coexistence of a malignant disease increases the possibility of lymphadenopathy being malignant in nature (2). The differentiation between malignant and nonmalignant FDG uptake may require histopathological confirmation.

Sarcoid-like reaction has been reported to be associated with malignancy and/or therapy (3). This case highlights the importance of confirming unexpected FDG PET/CT findings with histopathology to avoid unnecessary treatment in nonneoplastic conditions.

METHODS

A 38-year-old woman presented with lymphadenopathy. Lymph node biopsy confirmed nodular sclerosing Hodgkin lymphoma, and she was referred for staging FDG PET/CT. Intense FDG uptake was seen in multiple nodal stations above the diaphragm and spleen and extranodal involvement in the left lung and in T1, T2, and T5 vertebral bodies (Figure 1).

The patient underwent radiotherapy and 6 cycles of chemotherapy (escalated BEACCOP). End-of-treatment FDG PET/CT (5 months following diagnosis) showed significant metabolic and anatomic response in the previously FDG-avid multiple nodal stations above the diaphragm and spleen, but it revealed uptake in the periportal region (Figure 2).

A progress FDG PET/CT 6 months following diagnosis (with no interim treatment) showed widespread FDG-avid uptake in nonenlarged lymph nodes in multiple nodal stations above (hilar lymph nodes, arrowheads) and below the diaphragm, spleen, and multiple bones was highly suspicious of recurrent disseminated FDG-avid lymphoma (Figure 3). The patient was clinically well; the concern about early relapse resulted in bone marrow biopsy that demonstrated sarcoid-like granulomatous inflammation without evidence of Hodgkin disease. Other laboratory tests showed normal corrected calcium level, 2.40 mmol/L (NR, 2.20–2.55); normal angiotensin-converting enzyme, 35 μU/L (NR < 40); autoimmune serology, negative; blood cultures, negative; and blood culture for mycobacteria, negative.

© 2018 The Authors. Published by Grapho Publications, LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ISSN 2379-1381 http://dx.doi.org/10.18383/j.tom.2017.00022
The patient did not receive any treatment. A further FDG PET/CT 8 months following diagnosis confirmed resolution of uptake in lymph nodes, spleen, and bone (Figure 4).

**DISCUSSION**

Granulomatous lymphadenitis is a rare condition and is classified into 2 different groups: noninfectious and infectious. The noninfectious type includes berylliosis, Hodgkin lymphoma, non-Hodgkin lymphoma, lymph node-draining neoplasms (sarcoïd-like granuloma), and sarcoidosis. The infectious type can be categorized into suppurative lymphadenitis and nonsuppurative lymphadenitis. Suppurative lymphadenitis occurs in tularemia, cat scratch disease, Yersinia lymphadenitis, and lymphogranuloma venereum. Nonsuppurative lymphadenitis includes tuberculosis and Bacille Calmette–Guerin (BCG)-lymphadenitis (4, 5).

Sarcoidosis is a disease of unknown origin, with a global incidence of cases 8/100 000. It involves multiple organs, including pulmonary hilar lymph nodes, lungs, eyes, and skin (4). Useful diagnostic tests include demonstration of bilateral hilar lymphadenopathy on X-ray or CT, hypercalcemia, elevated angiotensin-converting enzyme level, and negative tuberculin test and histopathology (4).

Sarcoïd-like reaction refers to the presence of noncaseating granuloma in regional lymph nodes in patients with occult or evident disease without fulfilling the criteria for systemic sarcoidosis (6) and may occur in many solid tumors and draining lymph nodes, such as those draining carcinomas of lung, stomach, uterus, ovaries, and melanoma (7, 8, 9). Sarcoïd-like reaction has also been reported in tumors that have been treated with chemotherapy and radiotherapy (10, 11) and in nonregional tissue including bone marrow and spleen (12). The reported incidence is 13.8% of Hodgkin lymphoma and 7.3% of non-Hodgkin lymphomas (12). The clinical symptoms usually depend on the underlying disease. There is no hilar lymphadenopathy on X-ray and the tuberculin test is also negative. A biological defense mechanism in regional lymph nodes against antigens produced by tumor cells is postulated to be the reason for this reaction (13).

Tularemia is a zoonotic infection, a rare, often serious, disease, which affects ~125 people in the USA annually. The average incubation period is 3–5 days. The disease starts with an acute onset of nonspecific symptoms including, fever, anorexia, and general weakness. The diagnosis is confirmed by serology, polymerase chain reaction, and culture (14).

Other infectious types of granulomatous lymphadenitis can be diagnosed with serology, and culture with histopathology of...
The lymph node may be helpful (4). The distribution is variable with cat scratch disease and tularemia usually involving the cervical and axillary nodes, while Yersinia lymphadenitis involves mesenteric nodes and lymphogranuloma venereum the inguinal nodes (4).

CONCLUSION
This case illustrates the importance of confirming unexpected PET/CT findings with histopathology in avoiding unnecessary toxic treatment in non-neoplastic conditions.

REFERENCES
1. El-Galaly TC, Gormsen LC, Hutchings M. PET/CT for staging; past, present, and future. Semin Nucl Med. 2018;48:4-16.
2. Corrigan AJ, Schleyer PJ, Cook GJ. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin Nucl Med. 2015;45(6):481-499.
3. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25:326-333.
4. Asano S. Granulomatous lymphadenitis. J Clin Exp Hematop. 2012;52(1):1-16.
5. Subramanian S, Sandeepa HS, Chaudhari P, Kate AH, Kumar S, Shah P, Chhajed PN. Mediastinal lymphadenopathy in malignancy: metastatic or granulomatous? J Assoc Physicians India. 2014;63:630-632.
6. Inoue K, Goto R, Shimomura H, Fukuda H. FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. Springerplus 2013;2:113.
7. Brincker H. Interpretation of granulomatous lesions in malignancy. Acta Oncol. 1992;31:85-89.
8. Montag TW, Dyer LL, Spirto NM, James LP. Sarcoid-like lesions associated with epithelial ovarian adenocarcinoma. Obstet Gynecol. 1991;78:978-980.
9. Robert C, Schonenlaub P, Avril MF, Lok C, Grosshans E, Valeyre D, Bourgeois C, Pinquier L, Dubertret L, Guillame JC. Malignant melanoma and granulomatosis. Br J Dermatol. 1997;137:787-792.
10. Coyne JD. Necrobiotic palisading granulomas associated with breast carcinoma. J Clin Pathol. 2003;58:1290-1293.
11. James DG. A clinicopathological classification of granulomatous disorders. Postgrad Med J. 2000;76:457-465.
12. Bodem CR, Hamory BH, Taylor HM, Kleepper L. Granulomatous bone marrow disease. A review of the literature and clinicopathologic analysis of 58 cases. Medicine (Baltimore). 1983;62:372-383.
13. Brincker H. Sarcoid reactions in malignant tumors. Cancer Treat Rev. 1986;13:147-156.
14. Jon KF. Update on Emerging Infections: News From the Centers for Disease Control and Prevention. Ann Emerg Med. 2016;68:118-119.